BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11401666)

  • 1. S100A6 expression in fibrohistiocytic lesions.
    Fullen DR; Reed JA; Finnerty B; McNutt NS
    J Cutan Pathol; 2001 May; 28(5):229-34. PubMed ID: 11401666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
    West KL; Cardona DM; Su Z; Puri PK
    Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
    Li N; McNiff J; Hui P; Manfioletti G; Tallini G
    Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
    Kahn HJ; Fekete E; From L
    Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 protein immunoreactivity in fibrohistiocytic tumors of the skin.
    Lee CS; Chou ST
    Pathology; 1998 Aug; 30(3):272-5. PubMed ID: 9770192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
    Franchi A; Santucci M
    Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A6 preferentially labels type C nevus cells and nevic corpuscles: additional support for Schwannian differentiation of intradermal nevi.
    Fullen DR; Reed JA; Finnerty B; McNutt NS
    J Cutan Pathol; 2001 Sep; 28(8):393-9. PubMed ID: 11493376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of S100A6 protein in a broad spectrum of cutaneous tumors using tissue microarrays.
    Fullen DR; Garrisi AJ; Sanders D; Thomas D
    J Cutan Pathol; 2008 Nov; 35 Suppl 2():28-34. PubMed ID: 18201235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
    Taniuchi K; Yamada Y; Nonomura A; Takehara K
    J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
    Goldblum JR; Tuthill RJ
    Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ.
    King R; Googe PB; Page RN; Mihm MC
    Mod Pathol; 2005 Aug; 18(8):1043-7. PubMed ID: 15803191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique biphasic variant of cutaneous fibrous histiocytoma with a storiform pattern and intralesional pigmented melanocytes: "storiform melano-fibrous histiocytoma".
    Nair V; Weinreb I; MacNeil N; Szollosi Z; Chetty R; Ghazarian D
    Eur J Dermatol; 2008; 18(3):332-6. PubMed ID: 18474466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions.
    Böni R; Burg G; Doguoglu A; Ilg EC; Schäfer BW; Müller B; Heizmann CW
    Br J Dermatol; 1997 Jul; 137(1):39-43. PubMed ID: 9274623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
    Abenoza P; Lillemoe T
    Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nm23 protein expression and p53 immunoreactivity in cutaneous fibrohistiocytic tumors.
    Lee CS; Clarke RA; Tran KT; Kearsley JH; Chou ST
    Pathology; 1999 May; 31(2):123-6. PubMed ID: 10399167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrohistiocytic Tumors.
    Romano RC; Fritchie KJ
    Clin Lab Med; 2017 Sep; 37(3):603-631. PubMed ID: 28802503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans.
    McNiff JM; Subtil A; Cowper SE; Lazova R; Glusac EJ
    J Cutan Pathol; 2005 Jul; 32(6):413-8. PubMed ID: 15953374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
    Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
    Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.